Intercept Pharmaceuticals
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. We are committed to improving patients’ lives as we partner with leaders in the liver community to provide support and educational resources that help address unmet needs.